2 leaders in blood collection and transfusion technologies -- Fenwal and Golden Meditech -- form joint venture in China

Fenwal, Inc. of Lake Zurich, Illinois and Golden Meditech of Hong Kong have agreed to form a joint venture in China to focus on blood collection and transfusion products for the fast-growing Chinese medical market.

Medical professionals in China are expected to benefit from the combination of:

• Fenwal's technological leadership in blood collection, separation, preservation and transfusion, and
• Golden Meditech's expertise in China's blood-related medical device and blood-banking fields.

The joint venture will operate from Beijing and serve customers throughout China.

Initially, the joint venture will focus on sales and distribution of a range of Fenwal and Golden Meditech products – including the Fenwal AMICUS^® cell-separation system used to collect platelets; and the Golden Meditech 3000H Plasma Exchange system designed to remove toxins from patients' blood.

"Fenwal is a pioneer and leader in advanced blood technologies," said Mr. Kam Yuen, Golden Meditech chairman and chief executive officer. "We're looking to bring together the leadership, knowledge and capabilities of both companies to expand and customize our offerings for blood collection and transfusion medicine in China."

"Golden Meditech is a respected medical leader with extensive knowledge of the China market," said Ron Labrum, Fenwal president and chief executive officer. "Its people, technologies and infrastructure will complement Fenwal's current offerings in China. Together, we expect to create new opportunities to expand the market for advanced blood technologies that will benefit patients throughout China."

For more information, visit the companies’ websites at www.fenwalinc.com and www.goldenmeditech.com